ArticleScientific reports2025
Comprehensive identification of dysregulated extracellular matrix molecules in the corneal endothelium of patients with Fuchs endothelial corneal dystrophy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Targeting RhoA/ROCK Signaling to Modulate Extracellular Matrix Remodeling in Corneal Endothelial Dystrophies.Investigative ophthalmology & visual science · 2026Article
- Guttae modifying effect following intracameral injection of magnetically delivered human corneal endothelial cells in Fuchs endothelial corneal dystrophy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Pathological classification of Fuchs endothelial corneal dystrophy into several types and their relationships with CTG18.1 expansion repeats.The Journal of pathology · 2026Article
- Dome-Shaped Protrusions on Descemet's Membrane in Bullous Keratopathy: Identification and Histopathological Examination.Translational vision science & technology · 2026Observational
- Early Transcriptomic and Pathologic Changes of Col8a2 Mutant Fuchs Endothelial Corneal Dystrophy.Investigative ophthalmology & visual science · 2026Article
- AMF30a promotes survival and function of human corneal endothelial cells by regulating TGF-β/ROCK/HIPPO pathway.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Fuchs endothelial corneal dystrophy (FECD) is a bilateral, progressive corneal endothelial disease characterized by the formation of extracellular matrix (ECM) excrescences called guttae. This study integrated proteomic and transcriptomic analyses to elucidate the molecular composition and spatial organization of ECM proteins in the Descemet membrane (DM) of FECD patients. Through shotgun proteomics of FECD-derived DM specimens and RNA sequencing data from FECD (n = 10) and control (n = 7) corneal endothelial cells, we identified 19 significantly upregulated molecules in FECD, including 13 ECM-related proteins. Gene Ontology and Reactome analyses revealed ECM-related pathways as central to FECD pathology. Immunofluorescence analyses of flat-mounted and cross-sectional specimens from FECD patients undergoing Descemet membrane endothelial keratoplasty (DMEK) and controls demonstrated distinct spatial patterns for six ECM proteins. Fibronectin and collagen VI α1 were detected on the outer surfaces of guttae, matrilin-3 and biglycan localized around guttae, while LTBP2 and tenascin were strongly associated with the posterior fibrillar layer (PFL). The peripheral corneal regions predominantly exhibited scattered guttae, whereas the central region displayed buried guttae encapsulated by ECM deposition. This study comprehensively examined ECM protein expression patterns, revealing distinct spatial distributions across guttae, PFL, and surrounding DM regions. These findings suggest that clinical assessments should incorporate both guttae confluence and the presence of ECM-rich PFL to achieve a more comprehensive understanding of FECD progression, thereby informing more accurate staging and optimal surgical planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.